German Pharma Industry Cries Foul As Preliminary Evaluation Of AMNOG Suggests It Works
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.
You may also be interested in...
German Drug Report Could Mean More Pressure On Pharma Revenues
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
German HTA Blueprint Could Be Imposed On Greece
Germany’s role in preparing a health reform agreement between Greece and the World Health Organization may lead to a G-BA/IQWiG-style HTA process being introduced in the Hellenic Republic.
Germany’s IQWiG: New Year, Same Sternness On Dossier Structure
Pfizer’s kidney cancer drug Inlyta scrapes through the German added value assessment process but Almirall’s COPD product Eklira gets a “thumbs down,” showing that comparator selection is not the only deciding factor in the process.